Oncolytics Biotech Inc
TSX:ONC

Watchlist Manager
Oncolytics Biotech Inc Logo
Oncolytics Biotech Inc
TSX:ONC
Watchlist
Price: 14.9 CAD -1.32% Market Closed
Market Cap: 173.1m CAD

Relative Value

There is not enough data to reliably calculate the relative value of ONC.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ONC Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7.8
vs History
vs Industry
Median 3Y
-0.7
Median 5Y
-0.9
Industry
24.1
Forward
-5.6
vs History
vs Industry
7
Median 3Y
-0.8
Median 5Y
-1
Industry
21.8
vs History
vs Industry
5
Median 3Y
-0.8
Median 5Y
-1
Industry
23.8
vs History
1
vs Industry
7
Median 3Y
1.2
Median 5Y
1
Industry
3.3
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.3
vs History
vs Industry
Median 3Y
0.2
Median 5Y
0.3
Industry
6.3
Forward
-2.5
vs History
vs Industry
Median 3Y
0.2
Median 5Y
0.3
Industry
6.7
Forward
-3.7
vs History
vs Industry
8
Median 3Y
0.3
Median 5Y
0.4
Industry
7.9
vs History
vs Industry
7
Median 3Y
0.3
Median 5Y
0.3
Industry
6.3
vs History
1
vs Industry
14
Median 3Y
-1.8
Median 5Y
-2.9
Industry
5.5

Multiples Across Competitors

ONC Competitors Multiples
Oncolytics Biotech Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CA
Oncolytics Biotech Inc
TSX:ONC
173.1m CAD 0 -5.7 -5.2 -5.1
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 861 489.7 -160 938.6 -195 430.8 -193 200.7
US
Abbvie Inc
NYSE:ABBV
400.9B USD 6.7 170.7 16.5 23.4
US
Amgen Inc
NASDAQ:AMGN
176.1B USD 4.9 25.1 18.1 18.1
US
Gilead Sciences Inc
NASDAQ:GILD
154.4B USD 5.3 19 12.8 12.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.9B USD 9.9 31.5 23.1 24.2
US
Epizyme Inc
F:EPE
94.1B EUR 2 080.5 -530.9 -578.1 -562.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.9B USD 5.7 17.7 16.8 19.1
AU
CSL Ltd
ASX:CSL
85.2B AUD 3.6 18.8 12.7 15.8
NL
argenx SE
XBRU:ARGX
45B EUR 14.6 34.4 59.4 61
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.7B USD 16.4 1 210.8 159.1 192.9
P/S Multiple
Revenue Growth P/S to Growth
CA
Oncolytics Biotech Inc
TSX:ONC
Average P/S: 3 386 363.7
Not Available
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 861 489.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.7
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.9
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.3
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.9
10%
1
US
E
Epizyme Inc
F:EPE
2 080.5
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.7
6%
0.9
AU
CSL Ltd
ASX:CSL
3.6
5%
0.7
NL
argenx SE
XBRU:ARGX
14.6
49%
0.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.4
46%
0.4
P/E Multiple
Earnings Growth PEG
CA
Oncolytics Biotech Inc
TSX:ONC
Average P/E: 191
Negative Multiple: -5.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 938.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
170.7
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25.1
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
19
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.5
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -530.9 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.7
9%
2
AU
CSL Ltd
ASX:CSL
18.8
11%
1.7
NL
argenx SE
XBRU:ARGX
34.4
40%
0.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 210.8
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CA
Oncolytics Biotech Inc
TSX:ONC
Average EV/EBITDA: 39.8
Negative Multiple: -5.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 430.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.5
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.1
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.8
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.1
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -578.1 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.8
11%
1.5
AU
CSL Ltd
ASX:CSL
12.7
8%
1.6
NL
argenx SE
XBRU:ARGX
59.4
807%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
159.1
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CA
Oncolytics Biotech Inc
TSX:ONC
Average EV/EBIT: 45.9
Negative Multiple: -5.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -193 200.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.4
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.1
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.8
12%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.2
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -562.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.1
13%
1.5
AU
CSL Ltd
ASX:CSL
15.8
11%
1.4
NL
argenx SE
XBRU:ARGX
61
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
192.9
N/A N/A